Press Releases

    • MAY 05 2015

    Proprietary Discovery Method for First-in-class ONC201 Published

    Hummelstown, PA (May 05, 2015) – Oncoceutics, Inc. announced publication of a research article in the journal Molecular Cancer, which describes the discovery of ONC201 as a selective lead compound with a novel chemical structure and novel mechanism of action that warranted clinical testing.In an attempt to identify inducers of tumor cell death that spare

    • MAR 31 2015

    ONC201 Featured in Seven Abstracts at 2015 AACR Meeting

    Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for